Fabien Calvo, Jean-Luc Harousseau and Dominique Maraninchi are respectively Emeritus Professor of Pharmacology at the University of Paris-Diderot, former Professor of Hematology at the University of Nantes and Emeritus Professor of Cancerology at Aix-Marseille University.
A passionate controversy has developed in France and around the world on the use of early medical treatment of Covid-19, combining hydroxychloroquine and azithromicyne, following the work of Pr Didier Raoult.
Scientists and doctors clash both on the reality of the early reduction of the viral load which would prevent the most serious complications but especially on the absence of demonstration of the benefit in a "randomized" trial (which applies the rules having for goal of evaluating the effectiveness of a treatment, in particular the use of lottery, to determine which patients will be part of the group that will try the treatment, note). Ongoing European trial may not meet concept
This article is for subscribers only. You still have 88% to discover.
Subscribe: € 1 the first month
cancellable at any time
Enter your emailAlready subscribed? Log in